References
- Alessi D. R., Cohen P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 1998; 8(1)55–62, [PUBMED], [INFOTRIEVE], [CSA]
- Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 1996; 8(6)805–814, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 1997; 237(1)1–6, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bartkova J., Lukas J., Bartek J. Aberrations of the G1‐ and G1/S‐regulating genes in human cancer. Prog. Cell Cycle Res. 1997; 3: 211–220, [PUBMED], [INFOTRIEVE], [CSA]
- Bernards R. E2F: a nodal point in cell cycle regulation. Biochim. Biophys. Acta 1997; 1333(3)M33–M40, [PUBMED], [INFOTRIEVE]
- Black A. R., Azizkhan‐Clifford J. Regulation of E2F: a family of transcription factors involved in proliferation control. Gene 1999; 237(2)281–302, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brazil D. P., Hemmings B. A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 2001; 26(11)657–664, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brennan P., Babbage J. W., Burgering B. M., Groner B., Reif K., Cantrell D. A. Phosphatidylinositol 3‐kinase couples the interleukin‐2 receptor to the cell cycle regulator E2F. Immunity 1997; 7(5)679–689, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cantrell D. A. T‐cell antigen receptor signal transduction. Immunology 2002; 105(4)369–374, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chan T. O., Rittenhouse S. E., Tsichlis P. N. AKT/PKB and other D3 phosphoinositide‐regulated kinases: kinase activation by phosphoinositide‐dependent phosphorylation. Ann. Rev. Biochem. 1999; 68: 965–1014, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Coffer P. J., Jin J., Woodgett J. R. Protein kinase B (c‐Akt): a multifunctional mediator of phosphatidylinositol 3‐kinase activation. Biochem. J. 1998; 335(Pt. 1)1–13, [PUBMED], [INFOTRIEVE]
- Connell‐Crowley L., Elledge S. J., Harper J. W. G1 cyclin‐dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr. Biol. 1998; 8(1)65–68, [CROSSREF]
- Contos J. J., Ishii I., Chun J. Lysophosphatidic acid receptors. Mol. Pharmacol. 2000; 58(6)1188–1196, [PUBMED], [INFOTRIEVE], [CSA]
- Datta S. R., Brunet A., Greenberg M. E. Cellular survival: a play in three Akts. Genes Dev. 1999; 13(22)2905–2927, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 1998; 10(2)262–267, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Eichholtz T., Jalink K., Fahrenfort I., Moolenaar W. H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 1993; 291(Pt. 3)677–680, [PUBMED], [INFOTRIEVE]
- Fukushima N., Ishii I., Contos J. J., Weiner J. A., Chun J. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 507–534, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gala S., Marreiros A., Stewart G. J., Williamson P. Overexpression of E2F‐1 leads to cytokine‐independent proliferation and survival in the hematopoietic cell line BaF‐B03. Blood 2001; 97(1)227–234, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gaulton G. N., Williamson P. Interleukin‐2 and the interleukin‐2 receptor complex. Chem. Immunol. 1994; 59: 91–114, [PUBMED], [INFOTRIEVE], [CSA]
- Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev. 1998; 8(1)28–35, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hiebert S. W., Packham G., Strom D. K., Haffner R., Oren M., Zambetti G., Cleveland J. L. E2F‐1:DP‐1 induces p53 and overrides survival factors to trigger apoptosis. Mol. Cell. Biol. 1995; 15(12)6864–6874, [PUBMED], [INFOTRIEVE]
- Jalink K., Hordijk P. L., Moolenaar W. H. Growth factor‐like effects of lysophosphatidic acid, a novel lipid mediator. Biochim. Biophys. Acta 1994; 1198(2–3)185–196, [PUBMED], [INFOTRIEVE]
- Johnson D. G., Schwarz J. K., Cress W. D., Nevins J. R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993; 365(6444)349–352, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Koh J. S., Lieberthal W., Heydrick S., Levine J. S. Lysophosphatidic acid is a major serum noncytokine survival factor for murine macrophages which acts via the phosphatidylinositol 3‐kinase signaling pathway. J. Clin. Invest. 1998; 102(4)716–727, [PUBMED], [INFOTRIEVE], [CSA]
- Lali F. V., Hunt A. E., Turner S. J., Foxwell B. M. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide‐dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin‐2‐stimulated T cells independently of p38 mitogen‐activated protein kinase. J. Biol. Chem. 2000; 275(10)7395–7402, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lopez‐Ilasaca M., Crespo P., Pellici P. G., Gutkind J. S., Wetzker R. Linkage of G protein‐coupled receptors to the MAPK signaling pathway through PI 3‐kinase gamma. Science 1997; 275(5298)394–397, [CROSSREF]
- Lukas J., Petersen B. O., Holm K., Bartek J., Helin K. Deregulated expression of E2F family members induces S‐phase entry and overcomes p16INK4A‐mediated growth suppression. Mol. Cell. Biol. 1996; 16(3)1047–1057, [PUBMED], [INFOTRIEVE]
- Lundberg A. S., Weinberg R. A. Control of the cell cycle and apoptosis. Eur. J. Cancer (1990) 1999; 35(4)531–539, [CROSSREF]
- Luquain C., Sciorra V. A., Morris A. J. Lysophosphatidic acid signaling: how a small lipid does big things. Trends Biochem. Sci. 2003; 28(7)377–383, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moolenaar W. H. Lysophosphatidic acid, a multifunctional phospholipid messenger. J. Biol. Chem. 1995; 270(22)12949–12952, [PUBMED], [INFOTRIEVE]
- Muller H., Helin K. The E2F transcription factors: key regulators of cell proliferation. Biochim. Biophys. Acta 2000; 1470(1)M1–M12, [PUBMED], [INFOTRIEVE]
- Nicholson K. M., Anderson N. G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002; 14(5)381–395, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ogawa H., Ishiguro K., Gaubatz S., Livingston D. M., Nakatani Y. A complex with chromatin modifiers that occupies E2F‐ and Myc‐responsive genes in G0 cells. Science 2002; 296(5570)1132–1136, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Prosperi E. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control. Prog. Cell Cycle Res. 1997; 3: 193–210, [PUBMED], [INFOTRIEVE], [CSA]
- Qin X. Q., Livingston D. M., Kaelin W. G., Adams P. D. Deregulated transcription factor E2F‐1 expression leads to S‐phase entry and p53‐mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A. 1994; 91(23)10918–10922, [PUBMED], [INFOTRIEVE], [CSA]
- Reif K., Burgering B. M., Cantrell D. A. Phosphatidylinositol 3‐kinase links the interleukin‐2 receptor to protein kinase B and p70 S6 kinase. J. Biol. Chem. 1997; 272(22)14426–14433, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Roussel M. F. Key effectors of signal transduction and G1 progression. Adv. Cancer Res. 1998; 74: 1–24, [PUBMED], [INFOTRIEVE], [CSA]
- Shan B., Lee W. H. Deregulated expression of E2F‐1 induces S‐phase entry and leads to apoptosis. Mol. Cell. Biol. 1994; 14(12)8166–8173, [PUBMED], [INFOTRIEVE]
- Shan B., Durfee T., Lee W. H. Disruption of RB/E2F‐1 interaction by single point mutations in E2F‐1 enhances S‐phase entry and apoptosis. Proc. Natl. Acad. Sci. U. S. A. 1996; 93(2)679–684, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sherr C. J. G1 phase progression: cycling on cue. Cell 1994; 79(4)551–555, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sherr C. J. Cancer cell cycles. Science 1996; 274(5293)1672–1677, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stephens L., Smrcka A., Cooke F. T., Jackson T. R., Sternweis P. C., Hawkins P. T. A novel phosphoinositide 3 kinase activity in myeloid‐derived cells is activated by G protein beta gamma subunits. Cell 1994; 77(1)83–93, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stevens C., La Thangue N. B. E2F and cell cycle control: a double‐edged sword. Arch. Biochem. Biophys. 2003; 412(2)157–169, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Stoyanov B., Volinia S., Hanck T., Rubio I., Loubtchenkov M., Malek D., Stoyanova S., Vanhaesebroeck B., Dhand R., Nurnberg B. Cloning and characterization of a G protein‐activated human phosphoinositide‐3 kinase. Science 1995; 269(5224)690–693, [PUBMED], [INFOTRIEVE]
- Thumser A. E., Voysey J. E., Wilton D. C. The binding of lysophospholipids to rat liver fatty acid‐binding protein and albumin. Biochem. J. 1994; 301(Pt. 3)801–806, [PUBMED], [INFOTRIEVE]
- Tigyi G. Physiological responses to lysophosphatidic acid and related glycero‐phospholipids. Prostaglandins Other Lipid Mediat. 2001; 64(1–4)47–62, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tigyi G., Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J. Biol. Chem. 1992; 267(30)21360–21367, [PUBMED], [INFOTRIEVE]
- Toker A., Cantley L. C. Signalling through the lipid products of phosphoinositide‐3‐OH kinase. Nature 1997; 387(6634)673–676, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Trimarchi J. M., Fairchild B., Verona R., Moberg K., Andon N., Lees J. A. E2F‐6, a member of the E2F family that can behave as a transcriptional repressor. Proc. Natl. Acad. Sci. U. S. A. 1998; 95(6)2850–2855, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Trimarchi J. M., Fairchild B., Wen J., Lees J. A. The E2F6 transcription factor is a component of the mammalian Bmi1‐containing polycomb complex. Proc. Natl. Acad. Sci. U. S. A. 2001; 98(4)1519–1524, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Trimarchi J. M., Lees J. A. Sibling rivalry in the E2F family. Nat. Rev. Cancer 2002; 3(1)11–20, [CSA]
- Vivanco I., Sawyers C. L. The phosphatidylinositol 3‐kinase AKT pathway in human cancer. Nat. Rev. Mol. Cell. Biol. 2002; 2(7)489–501